Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

10 Jul 2008 07:00

RNS Number : 7470Y
Angle PLC
10 July 2008
 



For Immediate Release

10 July 2008

ANGLE plc

ANGLE Long-term Management Contract Win

Contract Value Increased by £1.7m to £5.4m

ANGLE plc ('ANGLE' or the 'Company'), the intellectual property and technology commercialisation company, is pleased to announce that following confirmation of preferred bidder status in February 2008, it has now been awarded the long term management contract of the London Development Agency's (LDA) Knowledge Connect Programme. 

In addition, it was originally announced that the value of this contract to ANGLE would be £3.7 million over three years. However, as a result of the LDA’s success in principle in securing European ERDF funds to support the programme, ANGLE is today pleased to announce that, subject to contract finalisation, the value of the Programme will be increased by £1.7 million to £5.4 million, once again over the next three years.

The Knowledge Connect Programme aims to increase the level of business research and development in London by creating new collaborations between business and the London knowledge base, with a focus on enterprises that have not previously worked with this sector.
 
This flagship Programme, a core part of the LDA’s Knowledge Transfer Strategy, will engage with a minimum of 2,880 businesses and involve ANGLE working intensively with more than 470 businesses across London. The Programme is being established to raise the performance and aspirations of London’s businesses by providing effective support for research and development, knowledge transfer and innovation across the Capital.
 
ANGLE was selected following a competitive tendering process on the basis of its experience in delivering similar business support programmes in London, UK wide and internationally. Additionally ANGLE has developed techniques which it was able to demonstrate have secured successful knowledge transfer from academic and research institutions across the World and that have measurable business benefits for a wide range of small and medium sized enterprises (SMEs).

Andrew Newland, Chief Executive of ANGLE, said:

"ANGLE's Management services business is a key feature of the Company's business model. The division provides top line revenue, is profitable and cash generative. However, it also provides the Company with access to leading academic, research and science organisations internationally, raising the profile of the whole Group and providing access to high quality IP commercialisation opportunities.

The award of this contract is not only a further success for our Management services business, but also underlines our strategy of focusing on long-term contracts that have the potential to generate significant revenues and earnings for the Group. We are delighted to be working on this project with not only the London Development Agency, but also more broadly with London's business and research communities to help identify new opportunities and secure business growth through knowledge transfer and innovation.”

Garth Selvey, Chairman of ANGLE, added: 

"This project adds to the strength of our Management services business, which provides the platform for the creation of real value in ANGLE's Progeny operation.

The Board believes that in the last five years ANGLE has generated significant inherent value in its underlying portfolio of companies, several of which are now at a stage of development to potentially deliver substantial cash returns for shareholders."

Enquiries:

ANGLE plc

01483 295830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Mark Connelly, Stewart Wallace

 

0207 523 8350

Scott Harris 

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

Buchanan Communications

Suzanne Brocks, James Strong

 

0207 466 5000

Notes to Editors

Founded in 1994, ANGLE is an international venture management company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

ANGLE is an active investor in high growth companies in the medical and technology sectors in both the UK and the US, taking operational responsibility for the companies as subsidiaries during the development phase and maintaining a substantial shareholding and close involvement during the growth phase. ANGLE has significant holdings in 10 portfolio companies developing proven technologies targeting substantial commercial markets. ANGLE is listed on AIM (AGL.L); further information can be found on www.ANGLEplc.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUKAORWRRBRUR
Date   Source Headline
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent
26th Jan 20127:00 amRNSInterim Results
26th Jan 20127:00 amRNSNovocellus Update
26th Jan 20127:00 amRNSFundraising
23rd Jan 20127:01 amRNSParsortix Update
19th Jan 20127:00 amRNSNotice of Interim Results and Webcast
16th Dec 20117:00 amRNSParsortix Update - Validation for Lung Cancer
7th Dec 20117:00 amRNSParsortix Update
21st Nov 20117:00 amRNSShare Options
16th Nov 20117:00 amRNSNovocellus Update
15th Nov 20117:00 amRNSIssue of equity and Total Voting Rights
11th Nov 20117:00 amRNSValidation for Prostate Cancer
10th Nov 20117:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.